Let's not forget about Abbott Laboratories' impressive streak of 52 consecutive annual dividend increases, which also makes ...

Abbott Laboratories closed $4.01 short of its 52-week high ($121.64), which the company reached on March 8th.

The stock's fall snapped a two-day winning streak.

Over the past few years, Abbott Laboratories' (NYSE: ABT) business has been a bit of a roller coaster. The pandemic disrupted its medical device business, but it was later able to smooth out those ...

Abbott Laboratories' diabetes care segment recently added new products to its lineup. It should remain one of the company's key growth drivers over the long run. There are other good reasons to ...

In a report released yesterday, Larry Biegelsen from Wells Fargo maintained a Buy rating on Abbott Laboratories (ABT – Research Report), with a price target of $133.00. The company’s shares ...

Abbott Laboratories (ABT) stock saw a decline, ending the day at $114.88 which represents a decrease of $-3.25 or -2.75% from the prior close of $118.13. The stock opened at $117.5 and touched a low ...

Cardiovascular disease is rising, and Abbott Laboratories is well-positioned in the CVD treatment space. Read why I'm neutral ...

Fintel reports that on September 19, 2024, Piper Sandler initiated coverage of Abbott Laboratories (NYSE:ABT) with a Overweight recommendation. As of August 26, 2024, the average one-year price ...

The projected fair value for Abbott Laboratories is US$132 based on 2 Stage Free Cash Flow to Equity With US$116 share price, Abbott Laboratories appears to be trading close to its estimated fair ...

Keir Starmer is warning that the NHS must 'reform or die' today after a damning report found billions of pounds in extra ...